ITP and TTP: interpreting evidence in light of patient values

Abstract

In this issue of Blood, data presented by Zhou et al and Lim et al on the use of rituximab (RTX) to treat immune thrombocytopenia (ITP) and thrombotic thrombocytopenic purpura (TTP), respectively, illuminate the importance of considering patient values and preferences in the interpretation of clinical evidence.